UMEC/VI 217 62.5/25 (166) TIO 18 218 (163) 215 (176) Exercise Studies IIIa R, DB, 12 UMEC 125 50 yes PC, trial (19) UMEC 62.5 XO per 49 UMEC/VI (22) 125/25 and 144 lung UMEC/VI 2 (59) block 62.5/25 152 VI 25 (63) per PLA 76 (30) 170 (65) IIIa R, DB, 12 UMEC 125 41 PC, week (14) UMEC 62.5 XO per 41 UMEC/VI (17) 125/25 and 128 lung UMEC/VI 2 (51) block 62.5/25 130 VI 25 (55) per PLA 64 (25) 151 (55) Long Term Study IIIa Long R, DB, 52 UMEC 125 227 no term PG, week (133) UMEC/VI PC 125/25 227 (143) PLA 109 (66) The clinical development program included two doses of umeclidinium (62.5 µg and 125 µg) and umeclidinium/vilanterol (62.5/25 µg and 125/25 µg) and is comprised of 7 Phase IIIa studies that evaluated the efficacy and safety of umeclidinium in which a total of 1592 subjects were treated with umeclidinium monotherapy and 1053 were treated with
UMEC/VI 62.5/25 TIO 18 217 (166) 218 (163) 215 (176) Exercise Studies IIIa and lung R, DB, PC, XO block 12 per 2 per UMEC 125 UMEC 62.5 UMEC/VI 125/25 UMEC/VI 62.5/25 VI 25 PLA 50 (19) 49 (22) 144 (59) 152 (63) 76 (30) 170 (65) yes IIIa and lung R, DB, PC, XO block 12 per 2 per UMEC 125 UMEC 62.5 UMEC/VI 125/25 UMEC/VI 62.5/25 VI 25 PLA 41 (14) 41 (17) 128 (51) 130 (55) 64 (25) 151 (55) Long Term Study IIIa Long term R, DB, PG, PC 52 UMEC 125 UMEC/VI 125/25 PLA 227 (133) 227 (143) 109 (66) no The clinical development program included two doses of umeclidinium (62.5 µg and 125 µg) and umeclidinium/vilanterol (62.5/25 µg and 125/25 µg) and is comprised of 7 Phase IIIa studies that evaluated the efficacy and safety of umeclidinium in which a total of 1592 subjects were treated with umeclidinium monotherapy and 1053 were treated with week week trial